Stockscreener 앱 받기
18.39
2.48%
0.445
전일 마감가:
$17.95
열려 있는:
$18.07
하루 거래량:
249.63K
Relative Volume:
0.93
시가총액:
$501.86M
수익:
$11.88M
순이익/손실:
$-162.08M
주가수익비율:
-1.4735
EPS:
-12.484
순현금흐름:
$-156.43M
1주 성능:
+4.70%
1개월 성능:
-7.89%
6개월 성능:
+47.28%
1년 성능:
+38.62%
1일 변동 폭
$17.75
$18.77
1주일 범위
$17.05
$19.05
52주 변동 폭
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
명칭
Crescent Biopharma Inc
전화
617-430-5595
주소
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
18.20 | 501.59M | 11.88M | -162.08M | -156.43M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.01 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
895.78 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
280.46 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
159.96 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Piper Sandler | Overweight |
| 2026-01-21 | 개시 | Guggenheim | Buy |
| 2025-08-25 | 개시 | Jefferies | Buy |
| 2025-08-11 | 개시 | H.C. Wainwright | Buy |
| 2025-07-14 | 개시 | Wedbush | Outperform |
| 2025-06-25 | 개시 | Stifel | Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-11 | 개시 | Noble Capital Markets | Outperform |
| 2024-07-26 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-22 | 개시 | CapitalOne | Overweight |
| 2021-11-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-04-29 | 재개 | Stephens | Overweight |
| 2021-02-10 | 개시 | Piper Sandler | Overweight |
| 2020-05-21 | 개시 | Raymond James | Outperform |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-05 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-01-04 | 개시 | Oppenheimer | Outperform |
| 2018-12-18 | 개시 | H.C. Wainwright | Buy |
| 2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
| 2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 개시 | Chardan Capital Markets | Buy |
| 2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
| 2016-07-26 | 개시 | SunTrust | Buy |
| 2016-06-30 | 개시 | Rodman & Renshaw | Buy |
| 2015-03-17 | 재확인 | Stifel | Buy |
모두보기
Crescent Biopharma Inc 주식(CBIO)의 최신 뉴스
Crescent Biopharma Announces Grants of Inducement Awards | Associated Press | syndication news - Enidnews.com
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
CBIO: CR-001 and ADC pipeline aim for best-in-class oncology therapies, with pivotal data expected from 2027 - TradingView
HC Wainwright & Co. Initiates Coverage of Crescent Biopharma (CBIO) with Buy Recommendation - MSN
[Form 4] CRESCENT BIOPHARMA, INC. Insider Trading Activity - Stock Titan
Crescent Biopharma (CBIO) director receives grant of 11,050 stock options at $17.01 - Stock Titan
Crescent Biopharma director granted 11,050 options | CBIO Insider Trading - Stock Titan
Director at Crescent Biopharma (CBIO) receives option grant for 11,050 shares - Stock Titan
Fairmount-linked director awarded 11,050 CBIO options at $17.01 exercise price - Stock Titan
Crescent Biopharma shareholders back directors, pay and auditor - TipRanks
Crescent Biopharma (CBIO) investors back directors, auditor and annual say-on-pay - Stock Titan
Crescent Biopharma, Inc. to Present at Jefferies and Goldman Sachs Healthcare Conferences in June 2026 - Quiver Quantitative
Crescent Biopharma to Present at June Investor Conferences - GlobeNewswire
CBIO: Directors elected, auditor ratified, and executive compensation approved with annual advisory votes - TradingView
CBIO: All proposals, including director elections and auditor ratification, were approved - TradingView
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Crescent Biopharma (CBIO) and Erasca (ERAS) - The Globe and Mail
Crescent Biopharma Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Crescent Biopharma Rings the Closing Bell - Nasdaq
Crescent Biopharma downgraded by H.C. Wainwright - Quantisnow
H.C. Wainwright downgrades Crescent Biopharma stock rating to neutral By Investing.com - Investing.com South Africa
H.C. Wainwright downgrades Crescent Biopharma stock rating to neutral - Investing.com
CBIO Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineEarnings Decline Risk - newsline.com
Crescent Biopharma (CBIO) Edges Lower, Holds Near Key Support LevelBlock Trade Flow - The Legal Advocate
CBIO Q1 2026 Earnings: EPS Beat on Lower Net Loss as Pipeline AdvancesEarnings Forecast Report - newsline.com
Crescent Biopharma (CBIO) Surges 4.59% as Biotech Sector Gains MomentumWMA Signal - The Legal Advocate
Crescent Biopharma (CBIO) Q1 2026 Earnings: Narrower Loss Beats Estimates; Shares Edge LowerFree Cash Flow Trends - The Legal Advocate
CBIO Q1 2026 Earnings: Narrowed Loss Beat Estimates as Clinical Pipeline AdvancesDownward Estimate Revision - newsline.com
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB) - The Globe and Mail
CBIO: Four clinical studies launching in 2024 set up a data-rich 2027 for oncology pipeline decisions - TradingView
CBIO Q1 2026 Earnings: Narrower Loss Surprises, Pipeline Progress ContinuesDividend Growth Analysis - Newser
Crescent Biopharma Inc. (CBIO) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineDividend Cut Risk - Newser
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - Sahm
CBIO Q1 2026 Earnings: Narrowed Loss Beats Estimates as Clinical Pipeline ProgressesSegment Revenue Breakdown - The Legal Advocate
Crescent Biopharma (CBIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Crescent Biopharma to present CR-001 trial data at ASCO meeting - Investing.com Nigeria
Crescent Biopharma to present CR-001 trial data at ASCO meeting By Investing.com - Investing.com South Africa
Crescent Biopharma Announces Ongoing ASCEND Phase 1/2 Clinical Trial of CR-001 for Multiple Solid Tumor Types with Initial Data Expected in 2027 - Quiver Quantitative
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 ... - Caledonian Record
Crescent cancer trial takes CR-001 to ASCO 2026, first data expected in 2027 - Stock Titan
Tang Capital entities disclose 1,160,000-share stake in Crescent Biopharma (CBIO) - Stock Titan
New Forecasts: Here's What Analysts Think The Future Holds For Crescent Biopharma, Inc. (NASDAQ:CBIO) - 富途牛牛
Balyasny entities disclose 1.51M shares in Crescent Biopharma (CBIO) - Stock Titan
Crescent Biopharma gives 5 new hires options on 129,075 shares - Stock Titan
Number of shareholders of Crescent Biopharma, Inc. – NASDAQ:CBIO - TradingView
CBIO Crescent Bio jumps 4% as Q1 loss beats estimates by 27%, pipeline progress lifts investor confidence.Trading Community - Newser
Crescent Biopharma Inc (CBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.79%
자본화:
|
볼륨(24시간):